iloprost (Q20817139)

ILOPROST (English)

21 September 2016

C₂₂H₃₂O₄

1 reference

ILOPROST (English)

19 November 2016

CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O

1 reference

ILOPROST (English)

19 November 2016

CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O

1 reference

World Health Organisation international non-proprietary name

ILOPROST (English)

19 November 2016

1 reference

14 February 2018

iloprost (English)

1 reference

Iloprost (English)

medical condition treated

19 January 2016

pulmonary hypertension

1 reference

Drug Indications Extracted from FAERS

chronic pulmonary heart disease

2 October 2018

1 reference

Drug Indications Extracted from FAERS

significant drug interaction

2 October 2018

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

anagrelide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vortioxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

paroxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sertraline

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluvoxamine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluoxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(S)-duloxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

venlafaxine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

A reference set of clinically relevant adverse drug-drug interactions

enoxaparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dalteparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tinzaparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rac-warfarin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fondaparinux

1 reference

A reference set of clinically relevant adverse drug-drug interactions

heparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

phenindione

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rivaroxaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

apixaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

Prostaglandin I2 receptor

subject has role

agonist

1 reference

Open Targets Platform

https://platform.opentargets.org/drug/CHEMBL494

14 August 2023

reference URL

subject has role

vasodilator agent

1 reference

Medical Subject Headings

MeSH descriptor ID

D016285

platelet aggregation inhibitors

15 March 2018

1 reference

InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1

Medical Subject Headings

15 March 2018

Iloprost

0 references

Identifiers

InChI

1 reference

ILOPROST (English)

19 November 2016

2 references

ILOPROST (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

78919-13-8

2 references

iloprost (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=78919-13-8

8 April 2021

ChemSpider ID

4470703

criterion used

ChemSpider entry describing a chemical structure with undefined configuration of a stereocenter

1 reference

ChemSpider entry describing a chemical structure with an explicitly stated unknown configuration of a stereocenter

Iloprost (English)

19 November 2016

1 reference

(5E)-5-[(3aS,4R,5R,6aS)-5-Hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]hexahydro-2(1H)-pentalenylidene]pentanoic acid (English)

19 November 2016

2 references

ILOPROST (English)

19 November 2016

ChEBI ID

63916

mapping relation type

2 references

ILOPROST (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1

1 reference

reason for deprecated rank

ILOPROST (English)

19 November 2016

withdrawn identifier value

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

8 February 2021

2 references

inferred from InChIKey

1 reference

1 reference

DSSTOX compound identifier

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.163.887

27 December 2018

ECHA Substance Infocard ID

(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]pentanoic acid (English)

quotation

CAS no.: 78919-13-8 (English)

100.163.887

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.163.887

27 December 2018

(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]pentanoic acid (English)

quotation

CAS no.: 78919-13-8 (English)

1 reference

World Health Organisation international non-proprietary name numeric ID

Iloprost (English)

publication date

17 November 2015

4972

0 references

Guide to Pharmacology Ligand ID

0 references

Iloprost

1 reference

D10.251.355.255.550.775.125

Medical Subject Headings

14 March 2018

0 references

D23.469.050.175.725.775.125

0 references

0 references

1 reference

iloprost (English)

19 November 2016

1 reference

2 references

iloprost (English)

19 November 2016

MedlinePlus drug identifier

0 references

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

iloprost (English)

19 November 2016

0 references

1 reference

0 references

0 references

1 reference

26 January 2022

UMLS CUI

C0079594

1 reference